| US 7,592,368 B2 | ||
| Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | ||
| Roger Dennis Tung, Beverly, Mass. (US); Michael Robin Hale, Bedford, Mass. (US); Christopher Todd Baker, Waltham, Mass. (US); Eric Steven Furfine, Durham, N.C. (US); Istvan Kaldor, Durham, N.C. (US); Wieslaw Mieczylaw Kazmierski, Raleigh, N.C. (US); and Andrew Spaltenstein, Raleigh, N.C. (US) | ||
| Assigned to Vertex Pharmaceuticals Incorporated, Cambridge, Mass. (US) | ||
| Filed on Oct. 04, 2004, as Appl. No. 10/958,223. | ||
| Application 10/958223 is a division of application No. 10/370171, filed on Feb. 19, 2003, granted, now 6,838,474. | ||
| Application 10/370171 is a division of application No. 09/602494, filed on Jun. 23, 2000, granted, now 6,559,137. | ||
| Application 09/602494 is a continuation of application No. PCT/US98/04595, filed on Mar. 09, 1998. | ||
| Application PCT/US98/04595 is a continuation in part of application No. 08/998050, filed on Dec. 24, 1997, granted, now 6,436,989. | ||
| Prior Publication US 2005/0148548 A1, Jul. 07, 2005 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 31/34 (2006.01); C07D 307/02 (2006.01) | ||
| U.S. Cl. 514—473 [549/475] | 20 Claims |
1. A compound of formula I:
![]() A is selected from —R1—(C1-C6)-alkyl, which is optionally substituted with one or more groups independently selected from hydroxy, C1-C4 alkoxy, Ht, —O-Ht, —NR2—CO—N(R2)2 or —CO—N(R2)2; —R1—(C2-C6)-alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, C1-C4 alkoxy, Ht, —O-Ht, —N(R2)—C(O)—N(R2)2 or —CO—N(R2)2; or R7;
each R1 is independently selected from —C(O)—, —S(O)2—, —C(O)—C(O)—, —O—C(O)—, —O—S(O)2, —N(R2)—S(O)2—, —N(R2)—C(O)— or —N(R2)—C(O)—C(O)—;
each Ht is independently selected from C3-C7 cycloalkyl; C5-C7 cycloalkenyl; C6-C10 aryl; or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R2), O, S and S(O)n; wherein said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted
with one or more substituents independently selected from oxo, —OR2, SR2, —R2, —N(R2)2, —R2—OH, —CN, —C(O)O—R2, —C(O)—N(R2)2, —S(O)2—N(R2)2, —N(R2)—C(O)—R2, —C(O)—R2, —S(O)n—R2, —OCF3, —S(O)n-Q, methylenedioxy, —N(R2)—S(O)2—R2, halo, —CF3, —NO2, Q, —OQ, —OR7, —SR7, —R7, —N(R2)(R7) or —N(R7)2;
each R2 is independently selected from H, or (C1-C4)-alkyl optionally substituted with Q;
B, when present, is —N(R2)—C(R3)2—C(O)—;
each x is independently 0 or 1;
each R3 is independently selected from H, Ht, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C6)-cycloalkyl or (C5-C6)-cycloalkenyl; wherein any member of said R3, except H, is optionally substituted with one or more substituents selected from —OR2, —C(O)—NH—R2, —S(O)n—N(R2)2, Ht, —CN, —SR2, —CO2R2, N(R2)—C(O)—R2;
each n is independently 1 or 2;
G, when present, is selected from H, R7 or (C1-C4)-alkyl, or, when G is (C1-C4)-alkyl, G and R7 are bound to one another either directly or through a C1-C3 linker to form a heterocyclic ring; or when G is absent, the atom to which G is attached is bound directly to the R7 group in —OR7 with the concomitant displacement of one -ZM group from R7;
D and D′ are independently selected from Q; (C1-C6)-alkyl; (C2-C4)-alkenyl; (C3-C6)-cycloalkyl, which is optionally substituted with or fused to Q; or (C5-C6)-cycloalkenyl, which is optionally substituted with or fused to Q;
each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system;
or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected
from O, N, S, S(O)n or N(R2); wherein any ring in Q is optionally substituted with one or more groups selected from oxo,
—OR2, —R2, —N(R2)2, —N(R2)—C(O)—R2, —R2—OH, —CN, —C(O)OR2, —C(O)—N(R2)2, halo or —CF3;
E is selected from Ht; O-Ht; Ht-Ht; —O—R3; —N(R2) (R3); (C1-C6)-alkyl, which is optionally substituted with one or more groups selected from R4 or Ht; (C2-C6)-alkenyl, which is optionally substituted with one or more groups selected from R4 or Ht; (C3-C6)-saturated carbocycle, which is optionally substituted with one or more groups selected from R4 or Ht; or (C5-C6)-unsaturated carbocycle, which is optionally substituted with one or more groups selected from R4 or Ht;
each R4 is independently selected from —OR2, —SR2, —C(O)—NHR2, —S(O)2—NHR2, halo, —N(R2)—C(O)—R2, —N(R2)2 or —CN;
each R7 is independently selected from
![]() wherein each M is independently selected from H, Li, Na, K, Mg, Ca, Ba, —N(R2)4, (C1-C12)-alkyl, (C2-C12)-alkenyl, or —R6; wherein 1 to 4 —CH2 radicals of the alkyl or alkenyl group, other than the —CH2 that is bound to Z, is optionally replaced by a heteroatom group selected from O, S, S(O), S(O)2, or N(R2); and wherein any hydrogen in said alkyl, alkenyl or R6 is optionally replaced with a substituent selected from oxo, —OR2, —R2, N(R2)2, N(R2)3, R2OH, —CN, —C(O)OR2, —C(O)—N(R2)2, S(O)2—N(R2)2, N(R2)—C(O)—R2, C(O)R2, —S(O)n—R2, OCF3, —S(O)n—R6, N(R2)—S(O)2—R2, halo, —CF3, or —NO2;
M′ is H, (C1-C12)-alkyl, (C2-C12)-alkenyl, or —R6; wherein 1 to 4 —CH2 radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from O, S, S(O), S(O)2, or N(R2); and wherein any hydrogen in said alkyl, alkenyl or R6 is optionally replaced with a substituent selected from oxo, —OR2, —R2, —N(R2)2, N(R2)3, —R2OH, —CN, —CO2R2, —C(O)—N(R2)2, —S(O)2—N(R2)2, —N(R2)—C(O)—R2, —C(O)R2, —S(O)n—R2, —OCF3, —S(O)n—R6, —N(R2)—S(O)2—R2, halo, —CF3, or —NO2;
Z is CH3, O, S, N(R2)2, or, when M is not present, H;
Y is P or S;
X is O or S; and
R9 is C(R2)2, O or N(R2); and wherein when Y is S, Z is not S; and
R6 is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered
saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains
one or more heteroatoms selected from O, N, S, S(O)n or N(R2); and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from OH, C1-C4 alkyl, O—(C1-C4)-alkyl or O—C(O)—(C1-C4)-alkyl.
|